ZIMLABPharmaceuticals
Zim Laboratories Ltd — Profit & Loss Statement
₹60.26
-0.45%
Zim Laboratories Ltd Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Tax Effect Of Unusual Items | -0.73 Cr | -0.30 Cr | -0.20 Cr | -0.02 Cr |
| Tax Rate For Calcs | 0.32 | 0.27 | 0.31 | 0.31 |
| Normalized EBITDA | 49.86 Cr | 46.59 Cr | 58.45 Cr | 44.30 Cr |
| Total Unusual Items | -2.26 Cr | -1.12 Cr | -0.66 Cr | -0.06 Cr |
| Total Unusual Items Excluding Goodwill | -2.26 Cr | -1.12 Cr | -0.66 Cr | -0.06 Cr |
| Net Income From Continuing Operation Net Minority Interest | 12.17 Cr | 17.25 Cr | 24.43 Cr | 14.55 Cr |
| Reconciled Depreciation | 20.11 Cr | 15.95 Cr | 17.47 Cr | 16.03 Cr |
| Reconciled Cost Of Revenue | 168.74 Cr | 172.37 Cr | 199.94 Cr | 161.24 Cr |
| EBITDA | 47.59 Cr | 45.48 Cr | 57.79 Cr | 44.24 Cr |
| EBIT | 27.48 Cr | 29.52 Cr | 40.33 Cr | 28.21 Cr |
| Net Interest Income | -11.06 Cr | -6.79 Cr | -5.24 Cr | -8.02 Cr |
| Interest Expense | 9.47 Cr | 5.88 Cr | 4.97 Cr | 7.17 Cr |
| Interest Income | 0.33 Cr | 0.13 Cr | 0.34 Cr | 0.28 Cr |
| Normalized Income | 13.69 Cr | 18.06 Cr | 24.89 Cr | 14.59 Cr |
| Net Income From Continuing And Discontinued Operation | 12.17 Cr | 17.25 Cr | 24.43 Cr | 14.55 Cr |
| Total Expenses | 336.19 Cr | 328.75 Cr | 353.47 Cr | 303.16 Cr |
| Rent Expense Supplemental | 0.34 Cr | 0.21 Cr | 0.22 Cr | 0.51 Cr |
| Diluted Average Shares | 4.87 Cr | 4.87 Cr | 4.87 Cr | 4.87 Cr |
| Basic Average Shares | 4.87 Cr | 4.87 Cr | 4.87 Cr | 4.87 Cr |
| Diluted EPS | 2.50 | 3.54 | 5.01 | 2.99 |
| Basic EPS | 2.50 | 3.54 | 5.01 | 2.99 |
| Diluted NI Availto Com Stockholders | 12.17 Cr | 17.25 Cr | 24.43 Cr | 14.55 Cr |
| Net Income Common Stockholders | 12.17 Cr | 17.25 Cr | 24.43 Cr | 14.55 Cr |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | 12.17 Cr | 17.25 Cr | 24.43 Cr | 14.55 Cr |
| Minority Interests | -2000.00 | -1000.00 | 0.00 | — |
| Net Income Including Noncontrolling Interests | 12.16 Cr | 17.25 Cr | 24.43 Cr | 14.55 Cr |
| Net Income Continuous Operations | 12.16 Cr | 17.25 Cr | 24.43 Cr | 14.55 Cr |
| Tax Provision | 5.84 Cr | 6.40 Cr | 10.92 Cr | 6.49 Cr |
| Pretax Income | 18.01 Cr | 23.64 Cr | 35.35 Cr | 21.04 Cr |
| Other Non Operating Income Expenses | 0.48 Cr | 0.97 Cr | 0.44 Cr | 0.18 Cr |
| Special Income Charges | -2.26 Cr | -1.12 Cr | -0.66 Cr | -0.06 Cr |
| Write Off | 2.13 Cr | 1.10 Cr | 0.00 | 0.05 Cr |
| Impairment Of Capital Assets | 0.14 Cr | 0.00 | 0.66 Cr | 30000.00 |
| Net Non Operating Interest Income Expense | -11.06 Cr | -6.79 Cr | -5.24 Cr | -8.02 Cr |
| Total Other Finance Cost | 1.92 Cr | 1.04 Cr | 0.61 Cr | 1.14 Cr |
| Interest Expense Non Operating | 9.47 Cr | 5.88 Cr | 4.97 Cr | 7.17 Cr |
| Interest Income Non Operating | 0.33 Cr | 0.13 Cr | 0.34 Cr | 0.28 Cr |
| Operating Income | 26.70 Cr | 26.77 Cr | 35.26 Cr | 25.09 Cr |
| Operating Expense | 167.45 Cr | 156.37 Cr | 153.53 Cr | 141.92 Cr |
| Other Operating Expenses | 41.17 Cr | 42.20 Cr | 37.54 Cr | 29.78 Cr |
| Depreciation And Amortization In Income Statement | 20.11 Cr | 15.95 Cr | 17.47 Cr | 16.03 Cr |
| Amortization | 1.86 Cr | 2.86 Cr | 4.00 Cr | 3.14 Cr |
| Depreciation Income Statement | 18.26 Cr | 13.09 Cr | 13.47 Cr | 12.90 Cr |
| Selling General And Administration | 38.01 Cr | 35.73 Cr | 41.06 Cr | 44.58 Cr |
| Selling And Marketing Expense | 24.12 Cr | 24.48 Cr | 27.94 Cr | 32.70 Cr |
| General And Administrative Expense | 13.90 Cr | 11.25 Cr | 13.12 Cr | 11.89 Cr |
| Rent And Landing Fees | 0.34 Cr | 0.21 Cr | 0.22 Cr | 0.51 Cr |
| Gross Profit | 194.15 Cr | 183.14 Cr | 188.79 Cr | 167.00 Cr |
| Cost Of Revenue | 168.74 Cr | 172.37 Cr | 199.94 Cr | 161.24 Cr |
| Total Revenue | 362.89 Cr | 355.51 Cr | 388.73 Cr | 328.25 Cr |
| Operating Revenue | 362.89 Cr | 355.51 Cr | 388.73 Cr | 328.25 Cr |
| Other Special Charges | — | 0.02 Cr | — | — |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Zim Laboratories Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.